Coherus BioSciences Azioni (NASDAQ: CHRS)

Coherus BioSciences (NASDAQ:CHRS) Azioni

Coherus BioSciences

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company focused on the research, development and commercialization of innovative immunotherapies to treat cancer. Coherus is developing an innovative immuno-oncology pipeline which includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable a robust antitumor immunologic response and enhance outcomes for patients with cancer.

Coherus BioSciences Inc

WIIM

CHRS

Coherus BioSciences shares are trading higher after the company announced it completed UDENYCA franchise divestiture.

&nbsp;– $250 million post-close cash balance extends cash runway over two years into 2027, funding pipeline development through key data catalysts –
– Coherus to focus exclusively on its innovative novel oncology programs including: – LOQTORZI&#xAE;, a revenue-generating and differentiated PD-1 inhibitor; – Casdozokitug, a first-in-class interleukin-27 (IL-27) antagonist; – CHS-114, a highly selective CCR8 (chemokine receptor 8) antibody –
REDWOOD CITY, Calif., April 14, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. ((Coherus or the Company, NASDAQ:<a href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) today announced the completion of the previously announced divestiture of its UDENYCA (pegfilgrastim-cbqv) franchise (the Transaction) to Intas Pharmaceuticals Ltd. (Intas) pursuant to the asset purchase agreement (the Agreement) dated December 2, 2024 between Coherus and Intas in a deal valued at up to $558.4 million. Coherus received an upfront payment of $483.4 million, including $118.4 million for UDENYCA inventory, and is eligible to receive potential milestone payments of up to $75 million.
"With strong strategic execution, we have transformed the company while dramatically reducing our debt and leaving $250 million on the post-close balance sheet. This provides ample runway to achieve our mid-term corporate objectives, including maximizing LOQTORZI revenues, advancing our novel immuno-oncology candidates in combination with LOQTORZI to key data milestones in 2026, and progressing label expanding indications for LOQTORZI in novel combinations," said Denny Lanfear, Coherus Chairman and Chief Executive Officer. "Coherus is now an innovative, revenue-generating oncology company with a strong balance sheet, and a promising mid-stage pipeline focused on unmet needs."
Terms of the Transaction and Financial Details At the closing of the Transaction, which occurred on April 11, 2025, Coherus received an upfront cash payment of $483.4 million, subject to certain adjustments that will be finalized following the closing pursuant to the Agreement. After the closing, Coherus is eligible to receive two milestone payments totaling $75.0 million if Intas meets specified thresholds of net sales of UDENYCA. At the closing, Intas received identified assets related to the UDENYCA franchise, including the UDENYCA pre-filled syringe, the UDENYCA autoinjector, and UDENYCA ONBODY&#xAE;, and assumed identified liabilities. At the closing, <a href="https://www.globenewswire.com/Tracker?data=BxhYF1sknRX4WjYKx0BBTTPwbmAmDdVgEPfBhKVSTTFNqsWmvrO9Hr3HNoK_v_-soJNfxKQ6jip2NaxsAqB96R6vTb2CxProPKPAt6z0YjEAztVJRFu3m46VuYhp_tZUPF9DXPFeXrh4QxbPqbabLclhbbihUh65jnHAvLSWYL7gRYkvf7Fhz0Jz9j3lz0k-MWCZR4OzX2BtD-zA9zyxuy-y6ss_i-_0ezaaijPn9xE=">Accord BioPharma</a>, Inc. (Accord), the U.S. specialty division of Intas Pharmaceuticals, Ltd., focused on the development of oncology, immunology, and critical care therapies, assumed full responsibility for the UDENYCA franchise in the U.S.

Biotech

News

Guidance

Asset Sales

General

Coherus Completes Strategic Transformation With Successful Divestiture Of UDENYCA Franchise; Says $250M Post-Close Cash Balance Extends Cash Runway Over 2-Years Into 2027, Funding Pipeline Development Through Key Data Catalysts; Coherus To Focus Exclusively On Its Innovative Novel Oncology Programs

– Remaining $60 Million of outstanding convertible notes to be repurchased post-close of pending UDENYCA divestiture –
REDWOOD CITY, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (("Coherus" or the "Company, NASDAQ:<a href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) announced today that it has entered into privately negotiated transactions (the "Repurchases") with certain holders (the "Holders") of its 1.500% Convertible Senior Subordinated Notes due 2026 (the "Convertible Notes"), pursuant to which the Company agreed to repurchase approximately $170 million aggregate principal amount of the Convertible Notes from such holders at a cash repurchase price equal to 100% of their principal amount, together with the accrued and unpaid interest to, but excluding, the date of repurchase.
The Repurchases are conditioned upon, among other things, the closing of the previously announced divestiture of the UDENYCA (pegfilgrastim-cbqv) franchise pursuant to that certain asset purchase agreement (the "Agreement"), dated as of December 2, 2024 between the Company and Intas Pharmaceuticals Ltd. ("Intas"), a limited company incorporated in India (the "Transaction").
Following the closing of the Repurchases, approximately $60 million aggregate principal amount of Convertible Notes will remain outstanding. Following the closing of the Transaction, Coherus intends to conduct a repurchase offer for such remaining Convertible Notes pursuant to the Fundamental Change Repurchase Right (as defined in the indenture, dated as of April 17, 2020 (the "Indenture"), between the Company and U.S. Bank Trust Company, National Association, as trustee (the "Trustee")) at a cash repurchase price equal to 100% of their principal amount, together with the accrued and unpaid interest to, but excluding, the date of repurchase.

Buybacks

Coherus Announces Repurchase Of ~$170M Of Convertible Notes

Coherus To Present Data From Phase 1 Dose Expansion Study Of CHS-114 At 2025 American Association For Cancer Research Annual Meeting

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Buy and maintains $7 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Coherus BioSciences, Maintains $7 Price Target

Coherus Biosciences Projects Post-UDENYCA-Close Cash Of ~$250M And Cash Runway Projections Exceeding Two Years, Past Key Data Readouts Expected In 2026.

Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.13) by 115.38 percent. This is a 54.84 percent increase over losses of $(0.62) per share from the same period last year. The company reported quarterly sales of $54.144 million which beat the analyst consensus estimate of $47.270 million by 14.54 percent. This is a 40.84 percent decrease over sales of $91.524 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

Coherus BioSciences Q4 2024 Adj. EPS $(0.28) Misses $(0.13) Estimate, Sales $54.144M Beat $47.270M Estimate

<h3>Companies Reporting Before The Bell</h3>
• Franco-Nevada (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNV#NYSE">FNV</a>) is expected to report quarterly earnings at $0.89 per share on revenue of $305.85 million. 
• BioNTech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BNTX#NASDAQ">BNTX</a>) is projected to report quarterly earnings at $0.37 per share on revenue of $1.15 billion. 
• UroGen Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/URGN#NASDAQ">URGN</a>) is estimated to report quarterly loss at $0.72 per share on revenue of $25.25 million. 
• DarioHealth (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DRIO#NASDAQ">DRIO</a>) is expected to report quarterly loss at $0.14 per share on revenue of $7.39 million. 
• Fennec Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FENC#NASDAQ">FENC</a>) is estimated to report quarterly loss at $0.13 per share on revenue of $16.42 million. 
• Optical Cable (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCC#NASDAQ">OCC</a>) is estimated to report earnings for its first quarter. 
• Cohen &amp; Co (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/COHN#AMEX">COHN</a>) is expected to report earnings for its fourth quarter. 
• Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) is projected to report quarterly loss at $3.67 per share on revenue of $433 thousand. 
• Genie Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GNE#NYSE">GNE</a>) is estimated to report earnings for its fourth quarter. 
• Rand Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAND#NASDAQ">RAND</a>) is expected to report earnings for its fourth quarter. 
• Telos (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TLS#NASDAQ">TLS</a>) is expected to report quarterly loss at $0.09 per share on revenue of $25.55 million. 
• NET Power (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NPWR#NYSE">NPWR</a>) is likely to report earnings for its fourth quarter. 
• Willis Lease Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WLFC#NASDAQ">WLFC</a>) is estimated to report earnings for its fourth quarter. 
<h3>Companies Reporting After The Bell</h3>
• Ramaco Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/METCB#NASDAQ">METCB</a>) is projected to report earnings for its fourth quarter. 
• Ramaco Resources (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/METC#NASDAQ">METC</a>) is expected to report quarterly earnings at $0.04 per share on revenue of $176.04 million. 
• Grupo Supervielle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SUPV#NYSE">SUPV</a>) is expected to report quarterly earnings at $0.25 per share on revenue of $215.50 million. 
• One Group Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKS#NASDAQ">STKS</a>) is expected to report quarterly earnings at $0.28 per share on revenue of $239.77 million. 
• NCS Multistage Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NCSM#NASDAQ">NCSM</a>) is likely to report earnings for its fourth quarter. 
• Lineage Cell Therapeutics (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/LCTX#AMEX">LCTX</a>) is projected to report quarterly loss at $0.03 per share on revenue of $1.62 million. 
• Yalla Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YALA#NYSE">YALA</a>) is projected to report earnings for its fourth quarter. 
• Douglas Elliman (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOUG#NYSE">DOUG</a>) is expected to report quarterly loss at $0.08 per share on revenue of $233.65 million. 
• Great Elm Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GECC#NASDAQ">GECC</a>) is expected to report quarterly earnings at $0.35 per share on revenue of $11.46 million. 
• Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) is estimated to report quarterly loss at $0.02 per share on revenue of $9.90 million. 
• Greenlight Capital Re (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLRE#NASDAQ">GLRE</a>) is projected to report earnings for its fourth quarter. 
• Oracle (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ORCL#NYSE">ORCL</a>) is likely to report quarterly earnings at $1.49 per share on revenue of $14.39 billion. 
• Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) is likely to report quarterly loss at $0.18 per share on revenue of $43.88 million. 
• Redwire (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDW#NYSE">RDW</a>) is likely to report quarterly loss at $0.18 per share on revenue of $75.58 million. 
• TruBridge (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TBRG#NASDAQ">TBRG</a>) is estimated to report quarterly earnings at $0.38 per share on revenue of $84.38 million. 
• Quanex Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) is likely to report quarterly loss at $0.05 per share on revenue of $384.99 million. 
• Commercial Vehicle Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CVGI#NASDAQ">CVGI</a>) is likely to report quarterly loss at $0.07 per share on revenue of $158.36 million. 
• Viemed Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VMD#NASDAQ">VMD</a>) is expected to report quarterly earnings at $0.10 per share on revenue of $59.40 million. 
• LifeMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFMD#NASDAQ">LFMD</a>) is estimated to report quarterly loss at $0.06 per share on revenue of $57.34 million. 
• Seaport Entertainment (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/SEG#AMEX">SEG</a>) is likely to report earnings for its fourth quarter. 
• Limbach Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LMB#NASDAQ">LMB</a>) is likely to report quarterly earnings at $0.77 per share on revenue of $149.37 million. 
• PLAYSTUDIOS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYPS#NASDAQ">MYPS</a>) is expected to report quarterly earnings at $0.02 per share on revenue of $67.73 million. 
• Gaia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GAIA#NASDAQ">GAIA</a>) is estimated to report quarterly loss at $0.04 per share on revenue of $23.78 million. 
• System1 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SST#NYSE">SST</a>) is expected to report quarterly loss at $0.23 per share on revenue of $91.28 million. 
• Mission Produce (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVO#NASDAQ">AVO</a>) is projected to report quarterly earnings at $0.04 per share on revenue of $272.00 million. 
• StandardAero (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SARO#NYSE">SARO</a>) is likely to report quarterly earnings at $0.16 per share on revenue of $1.37 billion. 
• Paymentus Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAY#NYSE">PAY</a>) is likely to report quarterly earnings at $0.12 per share on revenue of $222.06 million. 
• HighPeak Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HPK#NASDAQ">HPK</a>) is estimated to report quarterly earnings at $0.14 per share on revenue of $246.32 million. 
• PGIM ETF Trust PGIM Portfolio Ballast ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/PBL#BATS">PBL</a>) is expected to report quarterly earnings at $0.52 per share on revenue of $147.18 million. 
• Hesai Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSAI#NASDAQ">HSAI</a>) is projected to report quarterly earnings at $0.14 per share on revenue of $121.19 million. 
• Vail Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) is projected to report quarterly earnings at $6.36 per share on revenue of $1.14 billion. 
• Mobile Infrastructure (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BEEP#AMEX">BEEP</a>) is likely to report earnings for its fourth quarter. 
• Auna (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AUNA#NYSE">AUNA</a>) is expected to report quarterly earnings at $0.13 per share on revenue of $296.50 million. 
• Asana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ASAN#NYSE">ASAN</a>) is expected to report quarterly loss at $0.01 per share on revenue of $187.84 million. 
• Flotek Industries (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTK#NYSE">FTK</a>) is projected to report quarterly earnings at $0.10 per share on revenue of $50.08 million. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALGS

ASAN

AUNA

Mobile Infrastructure Corporation Common Stock

BEEP

BNTX

COHN

CVGI

DOUG

DRIO

FENC

GAIA

GECC

GLRE

HSAI

LCTX

LFMD

METC

Ramaco Resources, Inc. - Class B Common Stock

METCB

MYPS

NCSM

NPWR

ORCL

RAND

SARO

STKS

SUPV

TBRG

URGN

WLFC

YALA

Earnings Scheduled For March 10, 2025

<a href="https://sam.gov/opp/eddac0c4e8a84c379880ebcda5f29054/view" title="https://sam.gov/opp/eddac0c4e8a84c379880ebcda5f29054/view">https://sam.gov/opp/eddac0c4e8a84c379880ebcda5f29054/view</a>

Contracts

Coherus Biosciences Awarded $27,626,788.30 Contract From Department Of Veterans Affairs For Pharmaceutical Preparation Manufacturing

Coherus Biosciences Announced Final Data From Its Phase 2 Open Label Clinical Trial Evaluating Casdozokitug In Combination With Atezolizumab And Bevacizumab (Bev) In Treatment Naïve Patients With Unresectable Locally Advanced Or Metastatic Hepatocellular Carcinoma

Coherus Biosciences Sees FY24 Prelim. Net Revenues $255M-$260M

- Randomized Phase 2 study initiated evaluating the combination of casdozokitug, toripalimab and bevacizumab in patients with liver cancer -
REDWOOD CITY, Calif., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc.&nbsp;(("Coherus, NASDAQ:<a href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) today announced that an abstract highlighting final clinical and biomarker data from its Phase 2 clinical trial evaluating casdozokitug (casdozo), a selective and potent IL-27-antagonistic antibody, in combination with atezolizumab (atezo) and bevacizumab (bev) in treatment naïve patients with unresectable locally advanced or metastatic hepatocellular carcinoma (HCC), has been selected for a poster presentation at the upcoming 2025 ASCO GI Annual Meeting, being held January 23-25, 2025, in San Fransisco, CA.

Coherus To Present Randomized Phase 2 Study Evaluating The Combination Of Casdozokitug, Toripalimab And Bevacizumab In Patients With Liver Cancer

Baird analyst Colleen Kusy maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Outperform and raises the price target from $4 to $6.

Baird Maintains Outperform on Coherus BioSciences, Raises Price Target to $6

<h3>Gainers</h3>
<ul>
<li>Janux Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>) shares moved upwards by 67.4% to $67.26 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.5 billion. </li>
<li>Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) shares rose 48.9% to $2.04. The company's market cap stands at $235.0 million. </li>
<li>Citius Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTOR#NASDAQ">CTOR</a>) stock moved upwards by 22.54% to $1.25. The market value of their outstanding shares is at $89.1 million. </li>
<li>Vir Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIR#NASDAQ">VIR</a>) shares rose 21.47% to $9.9. The market value of their outstanding shares is at $1.3 billion. </li>
<li>Kindly MD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDLY#NASDAQ">KDLY</a>) shares rose 19.29% to $1.36. The company's market cap stands at $8.1 million. </li>
<li>PepGen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEPG#NASDAQ">PEPG</a>) stock rose 18.76% to $7.09. The company's market cap stands at $231.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Purple Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PPBT#NASDAQ">PPBT</a>) stock decreased by 27.7% to $6.07 during Tuesday's pre-market session. The market value of their outstanding shares is at $205.8 million. </li>
<li>Gelteq (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GELS#NASDAQ">GELS</a>) shares decreased by 24.36% to $2.89. The market value of their outstanding shares is at $27.2 million. </li>
<li>Sharps Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STSS#NASDAQ">STSS</a>) stock decreased by 16.51% to $2.8. The company's market cap stands at $5.0 million. </li>
<li>Revelation Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REVB#NASDAQ">REVB</a>) stock declined by 14.73% to $0.81. The market value of their outstanding shares is at $3.4 million. </li>
<li>InspireMD (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NSPR#NASDAQ">NSPR</a>) shares fell 13.78% to $2.63. The company's market cap stands at $68.6 million. </li>
<li>Aptorum Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APM#NASDAQ">APM</a>) shares fell 12.31% to $0.74. The company's market cap stands at $4.0 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

CTOR

GELS

JANX

KDLY

NSPR

PEPG

PPBT

REVB

STSS

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

On Tuesday,&nbsp;Coherus BioSciences, Inc.&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) entered into an asset purchase agreement with Intas Pharmaceuticals Ltd for the divestiture of the Udenyca (pegfilgrastim-cbqv) franchise for <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/g42286067/coherus-announces-agreement-to-divest-udenyca-franchise-for-up-to-558-million-to-intas-pharmaceuti" rel="noreferrer noopener">up to $558.4 million</a>.
The deal consideration includes an upfront payment of $483.4 million, to be adjusted for inventory at the close, and $75 million in potential net sales milestone payments.
Coherus plans to use a portion of the transaction proceeds to fully repay the company&#8217;s $230 million in existing convertible notes due April 2026 and $49.1 million to buy out certain royalty obligations related to Udenyca.
&#8220;The proposed divestiture of Udenyca represents the successful execution of our strategy to focus R&amp;D and commercial resources on Coherus&#8217; innovative immuno-oncology portfolio and to strengthen our financial position,&#8221; said Denny Lanfear, Coherus chairman and chief executive officer.
The proposed transaction is expected to close by the end of Q1 2025.
Coherus intends to strengthen and sharpen its focus on advancing its immuno-oncology portfolio in combination with Loqtorzi, a next-generation, differentiated PD-1 marketed in the U.S. in two indications.
Additional partnerships evaluating Loqtorzi with other cancer agents are planned for 2025.
The company plans to initiate a Phase 2 trial of casdozokitug/toripalimab/bevacizumab in first-line (1L) hepatocellular carcinoma (HCC) in Q4 2024, with final data from Phase 2 trial of casdozokitug/atezolizumab/bevacizumab in 1L HCC in Q1 2025, and data from its Phase 1 study of casdozokitug/toripalimab in second to fourth line (2-4L) non-small cell lung cancer (NSCLC) in 1H 2025.
Coherus plans to:
<ul>
<li>Report Phase 1 monotherapy biopsy data and CHS-114/toripalimab combination safety data in head and neck squamous cell carcinoma (HNSCC) in 1H 2025.</li>
<li>Initiate a Phase 1b CHS-114/toripalimab combination dose optimization study in 2L head and neck squamous cell carcinoma in Q1 2025, with a first data readout expected in Q2 2026.</li>
<li>Initiate a Phase 1b CHS-114/toripalimab combination dose optimization study in 2L gastric cancer in Q1 2025, with a first data readout expected in Q2 2026.</li>
</ul>
Earlier this year, Coherus BioSciences divested its Cimerli ophthalmology franchise to&nbsp;Sandoz Group AG&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/SDZNY#OTC">SDZNY</a>)&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/SDZXF#OTC">SDZXF</a>)&nbsp;for $170 million plus an&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36716756/why-is-cancer-immunotherapy-focused-coherus-biosciences-stock-trading-higher-today" rel="noreferrer noopener">additional amount for inventory</a>.
Price Action: CHRS stock is up 41.6% at $1.94 at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/12/42272645/merus-licenses-us-commercialization-rights-for-cancer-potential-zenocutuzumab-analyst-highlight-merus-pipeline" target="_blank" rel="noreferrer noopener">Merus Licenses US Commercialization Rights For Cancer Potential Zenocutuzumab, Analyst Highlight Merus&#8217; Pipeline</a></li>
</ul>
Photo: Shutterstock

Health Care

Trading Ideas

SDZNY

SDZXF

Why Is Coherus BioSciences Stock Trading Higher On Tuesday?

Coherus Biosciences shares are trading higher after the company announced an agreement to divest its Udenyca franchise for $558.4 million.

<ul>
<li>This includes an upfront payment of $483.4 million, to be adjusted for inventory at close, and $75.0 million in potential net sales milestone payments. Coherus plans to use a portion of the transaction proceeds to fully repay the entirety of the Company's $230.0 million in existing convertible notes due April 2026 and $49.1 million to buy-out certain royalty obligations related to UDENYCA.</li>
<li>Coherus to focus exclusively on innovative immuno-oncology programs that include LOQTORZI, an FDA approved, next-generation programmed cell death protein 1 (PD-1) inhibitor.</li>
<li>Proceeds to fund development of key combination programs with LOQTORZI, including casdozokitug, a first-in-class, clinical-stage interleukin-27 (IL-27) antagonist, and CHS-114, a highly selective chemokine receptor 8 (CCR8) antibody.</li>
<li>Post-closing proceeds to repay the entirety of the company's $230 million convertible notes due April 2026</li>
</ul>

Coherus Biosciences Has Agreed To Divest Udenyca (Pegfilgrastim) Franchise To Intas Pharmaceuticals For Up To $558.4M

Baird analyst Colleen Kusy maintains Coherus BioSciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHRS#NASDAQ">CHRS</a>) with a Outperform and lowers the price target from $8 to $4.

Baird Maintains Outperform on Coherus BioSciences, Lowers Price Target to $4

Press Releases

Coherus Announces Agreement to Divest UDENYCA® Franchise for up to $558 million  to Intas Pharmaceuticals Ltd.

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Coherus Management to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Coherus Presents Final Phase 2 Clinical Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

Coherus Management to Participate at the 45th Annual TD Cowen Health Care Conference

Coherus to Report Fourth Quarter and Full Year 2024 Financial Results on March 10, 2025

Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

Coherus to Present Data from a Phase 1 Dose Expansion Study of CHS-114, a Cytolytic Antibody Targeting Chemokine Receptor 8 (CCR8), at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Coherus Announces Repurchase of Approximately $170 Million of Convertible Notes

Coherus Completes Strategic Transformation with Successful Divestiture of UDENYCA® Franchise

Comments

Coherus BioSciences

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO